{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:18:19Z","timestamp":1790774299640,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Follicular helper T-cell lymphoma (TFHL) is the most common non-cutaneous T-cell lymphoma in the Western world and is associated with a poor prognosis. Neoplastic cells rely heavily on the tumor microenvironment, demonstrated by the absence of TFHL-derived cell lines, which hinders therapeutic progress. To overcome this limitation, we developed and characterized patient-derived xenograft TFHL (TFHL-PDXs). Fifteen TFHLs were implanted into immunodeficient mice, generating nine PDXs. The tumor microenvironment was detected in the first passage but progressively disappeared in subsequent passages. <jats:italic>TET2<\/jats:italic> mutations persisted in all cases and TFHL-specific mutations were observed in most. The models were treated with azacitidine and patient sensitivity was fully recapitulated. To elucidate the mechanism of action of azacitidine, we analyzed the differences in DNA methylation and gene expression in six TFHL-PDX models. Global DNA hypomethylation occurred in azacitidine-treated cells in drug-sensitive models but not in the resistant ones. DNA hypomethylation was associated with global upregulation of gene expression, including that of various cancer-related pathways, suggestive of p53-pathway-mediated cytotoxicity. Overall, the PDXs recapitulated TFHL features and exhibited sensitivity to azacitidine. They also made it possible to decipher the mechanism responsible for the effect of azacitidine, revealing the activation of p53-mediated apoptosis associated with DNA hypomethylation.<\/jats:p>","DOI":"10.1038\/s41375-025-02628-0","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T09:46:55Z","timestamp":1747734415000},"page":"1744-1755","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Induction of p53-mediated apoptosis by azacitidine in patient-derived xenograft follicular helper T-cell lymphoma model"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9652-3751","authenticated-orcid":false,"given":"Gamze","family":"Tari Crochet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selcen","family":"Ari-Yuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7145-2544","authenticated-orcid":false,"given":"Anja","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5755-4620","authenticated-orcid":false,"given":"Mohamed","family":"Chour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7164-3930","authenticated-orcid":false,"given":"Alexis","family":"Claudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nouhoum","family":"Sako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrielle","family":"Robe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Naudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Gonon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana Laure","family":"Mboumba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Ortonne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1843-6286","authenticated-orcid":false,"given":"Vincent","family":"Alcazer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Delfau-Larue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiner","family":"Siebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gaulard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6205-5419","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Lemonnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"key":"2628_CR1","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1200\/JCO.2016.71.2083","volume":"35","author":"C Laurent","year":"2017","unstructured":"Laurent C, Baron M, Amara N, Haioun C, Dandoit M, Maynadi\u00e9 M, et al. Impact of expert pathologic review of lymphoma diagnosis: study of patients from the French Lymphopath Network. Journal Clin Oncol. 2017;35:2008\u201317.","journal-title":"Journal Clin Oncol"},{"key":"2628_CR2","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IB de O, Berti E, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36:1720\u201348.","journal-title":"Leukemia"},{"key":"2628_CR3","first-page":"1229","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood, J Am Soc Hematol. 2022;140:1229\u201353.","journal-title":"Blood, J Am Soc Hematol"},{"key":"2628_CR4","first-page":"4952","volume":"109","author":"de Leval","year":"2007","unstructured":"de Leval, Rickman L, Thielen DS, Reynies C, de A, Huang YL, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood, J Am Soc Hematol. 2007;109:4952\u201363.","journal-title":"Blood, J Am Soc Hematol"},{"key":"2628_CR5","first-page":"1466","volume":"120","author":"F Lemonnier","year":"2012","unstructured":"Lemonnier F, Couronn\u00e9 L, Parrens M, Ja\u00efs JP, Travert M, Lamant L, et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood, J Am Soc Hematol. 2012;120:1466\u20139.","journal-title":"Blood, J Am Soc Hematol"},{"issue":"janv","key":"2628_CR6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1056\/NEJMc1111708","volume":"366","author":"L Couronn\u00e9","year":"2012","unstructured":"Couronn\u00e9 L, Bastard C, Bernard OA. TET2 and DNMT3A mutations in human T-cell lymphoma. New Engl J Med. 2012;366(janv):95\u20136.","journal-title":"New Engl J Med"},{"issue":"f\u00e9vr","key":"2628_CR7","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1182\/blood-2011-11-391748","volume":"119","author":"RA Cairns","year":"2012","unstructured":"Cairns RA, Iqbal J, Lemonnier F, Kucuk C, de Leval L, Jais JP, et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood. 2012;119(f\u00e9vr):1901\u20133.","journal-title":"Blood"},{"key":"2628_CR8","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/ng.2872","volume":"46","author":"M Sakata-Yanagimoto","year":"2014","unstructured":"Sakata-Yanagimoto M, Enami T, Yoshida K, Shiraishi Y, Ishii R, Miyake Y, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nature Genet. 2014;46:171\u20135.","journal-title":"Nature Genet"},{"key":"2628_CR9","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/ng.2873","volume":"46","author":"T Palomero","year":"2014","unstructured":"Palomero T, Couronn\u00e9 L, Khiabanian H, Kim MY, Ambesi-Impiombato A, Perez-Garcia A, et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nature Genet. 2014;46:166\u201370.","journal-title":"Nature Genet"},{"key":"2628_CR10","first-page":"1490","volume":"128","author":"D Vallois","year":"2016","unstructured":"Vallois D, Dobay MPD, Morin RD, Lemonnier F, Missiaglia E, Juilland M, et al. Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell\u2013derived lymphomas. Blood, J Am Soc Hematol. 2016;128:1490\u2013502.","journal-title":"Blood, J Am Soc Hematol"},{"key":"2628_CR11","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1182\/bloodadvances.2020001636","volume":"4","author":"NE Lewis","year":"2020","unstructured":"Lewis NE, Petrova-Drus K, Huet S, Epstein-Peterson ZD, Gao Q, Sigler AE, et al. Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms. Blood Adv. 2020;4:2261\u201371.","journal-title":"Blood Adv"},{"key":"2628_CR12","doi-asserted-by":"publisher","first-page":"4640","DOI":"10.1182\/bloodadvances.2020002396","volume":"4","author":"P Ghione","year":"2020","unstructured":"Ghione P, Faruque P, Mehta-Shah N, Seshan V, Ozkaya N, Bhaskar S, et al. T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed\/refractory peripheral T-cell lymphoma. Blood Adv. 2020;4:4640\u20137.","journal-title":"Blood Adv"},{"key":"2628_CR13","first-page":"2305","volume":"132","author":"F Lemonnier","year":"2018","unstructured":"Lemonnier F, Dupuis J, Sujobert P, Tournillhac O, Cheminant M, Sarkozy C, et al. Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma. Blood, J Am Soc Hematol. 2018;132:2305\u20139.","journal-title":"Blood, J Am Soc Hematol"},{"key":"2628_CR14","doi-asserted-by":"publisher","first-page":"e406","DOI":"10.1016\/S2352-3026(24)00102-9","volume":"11","author":"J Dupuis","year":"2024","unstructured":"Dupuis J, Bachy E, Morschhauser F, Cartron G, Fukuhara N, Daguindau N, et al. Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study. Lancet Haematol. 2024;11:e406\u201314.","journal-title":"Lancet Haematol"},{"key":"2628_CR15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/9780470942390.mo110217","volume":"2","author":"T Burkholder","year":"2012","unstructured":"Burkholder T, Foltz C, Karlsson E, Linton CG, Smith JM. Health evaluation of experimental laboratory mice. Current Protoc mouse Biol. 2012;2:145\u201365.","journal-title":"Current Protoc mouse Biol"},{"key":"2628_CR16","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/s41379-022-01022-w","volume":"35","author":"A Nicolae","year":"2022","unstructured":"Nicolae A, Bouilly J, Lara D, Fataccioli V, Lemonnier F, Drieux F, et al. Nodal cytotoxic peripheral T-cell lymphoma occurs frequently in the clinical setting of immunodysregulation and is associated with recurrent epigenetic alterations. Modern Pathol. 2022;35:1126\u201336.","journal-title":"Modern Pathol"},{"key":"2628_CR17","doi-asserted-by":"publisher","first-page":"3916","DOI":"10.1002\/1878-0261.13311","volume":"16","author":"L Favre","year":"2022","unstructured":"Favre L, Sako N, Tarfi S, Quang VT, Joy C, Dupuy A, et al. Evaluation of two new highly multiplexed PCR assays as an alternative to next-generation sequencing for IDH1\/2 mutation detection. Molecular Oncol. 2022;16:3916\u201326.","journal-title":"Molecular Oncol"},{"key":"2628_CR18","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1182\/bloodadvances.2020003081","volume":"5","author":"F Lemonnier","year":"2021","unstructured":"Lemonnier F, Safar V, Beldi-Ferchiou A, Cottereau AS, Bachy E, Cartron G, et al. Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma. Blood Adv. 2021;5:539\u201348.","journal-title":"Blood Adv"},{"key":"2628_CR19","doi-asserted-by":"publisher","first-page":"e0166126","DOI":"10.1371\/journal.pone.0166126","volume":"11","author":"M Duez","year":"2016","unstructured":"Duez M, Giraud M, Herbert R, Rocher T, Salson M, Thonier F. Vidjil: a web platform for analysis of high-throughput repertoire sequencing. PloS one. 2016;11:e0166126.","journal-title":"PloS one"},{"key":"2628_CR20","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1002\/ajh.26647","volume":"97","author":"V Alcazer","year":"2022","unstructured":"Alcazer V, Bonaventura P, Tonon L, Michel E, Mutez V, Fabres C, et al. HERVs characterize normal and leukemia stem cells and represent a source of shared epitopes for cancer immunotherapy. American J Hematol. 2022;97:1200\u201314.","journal-title":"American J Hematol"},{"key":"2628_CR21","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.ccell.2023.01.003","volume":"41","author":"J Leca","year":"2023","unstructured":"Leca J, Lemonnier F, Meydan C, Foox J, El Ghamrasni S, Mboumba DL, et al. IDH2 and TET2 mutations synergize to modulate T Follicular Helper cell functional interaction with the AITL microenvironment. Cancer Cell. 2023;41:323\u2013339.e10.","journal-title":"Cancer Cell"},{"key":"2628_CR22","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1182\/bloodadvances.2019001114","volume":"4","author":"M Witalis","year":"2020","unstructured":"Witalis M, Chang J, Zhong MC, Bouklouch Y, Panneton V, Li J, et al. Progression of AITL-like tumors in mice is driven by Tfh signature proteins and TB cross talk. Blood Adv. 2020;4:868\u201379.","journal-title":"Blood Adv"},{"key":"2628_CR23","first-page":"1937","volume":"140","author":"M Fujisawa","year":"2022","unstructured":"Fujisawa M, Nguyen TB, Abe Y, Suehara Y, Fukumoto K, Suma S, et al. Clonal germinal center B cells function as a niche for T-cell lymphoma. Blood, J Am Soc Hematol. 2022;140:1937\u201350.","journal-title":"Blood, J Am Soc Hematol"},{"key":"2628_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03405-8","volume":"20","author":"S Abdolahi","year":"2022","unstructured":"Abdolahi S, Ghazvinian Z, Muhammadnejad S, Saleh M, Asadzadeh Aghdaei H, Baghaei K. Patient-derived xenograft (PDX) models, applications and challenges in cancer research. Journal Transl Med. 2022;20:206.","journal-title":"Journal Transl Med"},{"key":"2628_CR25","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/path.5376","volume":"250","author":"W Yao","year":"2020","unstructured":"Yao W, Wu F, Zhang W, Chuang S, Thompson JS, Chen Z, et al. Angioimmunoblastic T-cell lymphoma contains multiple clonal T-cell populations derived from a common TET2 mutant progenitor cell. Journal Pathol. 2020;250:346\u201357.","journal-title":"Journal Pathol"},{"key":"2628_CR26","first-page":"327","volume":"61","author":"CJ Kemp","year":"2001","unstructured":"Kemp CJ, Sun S, Gurley KE. p53 induction and apoptosis in response to radio-and chemotherapy in vivo is tumor-type-dependent. Cancer Res. 2001;61:327\u201332.","journal-title":"Cancer Res"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02628-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02628-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02628-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T06:05:05Z","timestamp":1751263505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02628-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2628"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02628-0","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"assertion":[{"value":"19 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GT, SAY, AF, MC, AC, NS, CR, JN, AG, DLM, MHDL, VA, RS, and PG have no conflict of interest to declare. FL has received a research grant from BMS and Roche, a travel grant from Roche, Gilead, and Abbvie, and honoraria grants from Takeda and AstraZeneca. FL is on the advisory board of Miltenyi, Kyowa Kirin, and BMS.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}